Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 29, 2016 (10 years ago)

Amikacin Sulfate Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Amikacin Sulfate Injection, USP, 1 gm/4 mL (250 mg/mL) Rx Only, Manufactured in Hungary For: Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0703-9040-01 (individual pack), NDC 0703-9040-03 (shelf-pack carton of 10 vials).

Affected NDCs 0703-9040-01 0703-9040-03

Compare with the code on your package — it is the most precise check available.

Drug: Amikacin

Recalling firm
Teva Pharmaceuticals USA
NDC code
0703-9040-01
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0024-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Amikacin recalls

See all
Class I · High risk

Amikacin Sulfate Injection

Non-Sterility:Microbial growth detected in sub lot of Amikacin Sulfate Injection, USP 1gm/4 mL (250mg/mL) and Prochlorperazine Edisylate Injection, USP 10mg/2mL (5mg/mL) .

Terminated Sterility / contamination Heritage Pharmaceuticals, Inc. NDC 23155-290-32 D-1398-2019

Other recalls by Teva Pharmaceuticals USA

All 2016 recalls